Zymax Pharma

Executive Summary

Zymax Pharma is a specialized pharmaceutical consultancy based in Ankleshwar, India, offering regulatory affairs and quality compliance services to API and intermediate manufacturers. Founded in 2020, the company assists clients in navigating global regulated markets, including FDA licensing, DMF/CEP/COS submissions, GMP implementation, and analytical method validation. While Zymax does not develop its own therapeutics, it supports manufacturers across therapeutic areas, with a focus on infectious disease through small molecule APIs. As a platform-stage company with 10-50 employees, Zymax operates as a service provider rather than a drug developer, limiting its direct exposure to product-related milestones. Its value is tied to client demand for regulatory expertise in emerging markets and the increasing complexity of global compliance standards.

Upcoming Catalysts (preview)

• TBDStrategic partnership with a top-tier API manufacturer45% success
• Q3 2026Expansion of service offerings into biologics or advanced intermediates30% success
• Q3 2026Receipt of ISO 9001 certification or similar quality accreditation60% success